Related Experiment Video
Updated: Aug 9, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma
Takafumi Narisawa1, Sei Naito2, Hiromi Ito2
1Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japan. tnari_0623@yahoo.co.jp.
Background:
Several clear cell renal cell carcinoma (ccRCC) cases harbour fibroblast growth factor receptor 4 (FGFR4) gene copy number (CN) gains. In this study, we investigated the functional contribution of FGFR4 CN amplification in ccRCC.
Methods:
The correlation between FGFR4 CN determined via real-time PCR and protein expression evaluated using western blotting and immunohistochemistry was assessed in ccRCC cell lines (A498, A704, and 769-P), a papillary RCC cell line (ACHN), and clinical ccRCC specimens. The effect of FGFR4 inhibition on ccRCC cell proliferation and survival was assessed via either RNA interference or using the selective FGFR4 inhibitor BLU9931, followed by MTS assays, western blotting, and flow cytometry. To investigate whether FGFR4 is a potential therapeutic target, a xenograft mouse model was administered BLU9931.
Results:
60% of ccRCC surgical specimens harboured an FGFR4 CN amplification. FGFR4 CN was positively correlated with its protein expression. All ccRCC cell lines harboured FGFR4 CN amplifications, whereas ACHN did not. FGFR4 silencing or inhibition attenuated intracellular signal transduction pathways, resulting in apoptosis and suppressed proliferation in ccRCC cell lines. BLU9931 suppressed tumours at a tolerable dose in the mouse model.
Conclusion:
FGFR4 contributes to ccRCC cell proliferation and survival following FGFR4 amplification, making it a potential therapeutic target for ccRCC.
Insights
Fibroblast growth factor receptor 4 (FGFR4) gene amplification drives clear cell renal cell carcinoma (ccRCC) growth. Inhibiting FGFR4 suppressed tumor progression, identifying it as a promising therapeutic target for ccRCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Clear cell renal cell carcinoma (ccRCC) frequently exhibits fibroblast growth factor receptor 4 (FGFR4) gene copy number (CN) gains.
- The functional role of FGFR4 CN amplification in ccRCC pathogenesis requires elucidation.
Purpose of the Study:
- To investigate the functional significance of FGFR4 CN amplification in ccRCC.
- To evaluate FGFR4 as a potential therapeutic target in ccRCC.
Main Methods:
- Assessed correlation between FGFR4 CN (real-time PCR) and protein expression (western blotting, immunohistochemistry) in ccRCC cell lines and clinical specimens.
- Utilized RNA interference and a selective FGFR4 inhibitor (BLU9931) to assess effects on ccRCC cell proliferation and survival (MTS assays, western blotting, flow cytometry).
- Evaluated BLU9931 efficacy in a ccRCC xenograft mouse model.
Main Results:
- FGFR4 CN amplification was observed in 60% of ccRCC specimens and correlated positively with protein expression.
- FGFR4 amplification was present in ccRCC cell lines but not in a papillary RCC cell line (ACHN).
- FGFR4 inhibition led to apoptosis and suppressed proliferation in ccRCC cells, with BLU9931 showing tumor suppression in vivo at tolerable doses.
Conclusions:
- FGFR4 amplification promotes ccRCC cell proliferation and survival.
- Targeting FGFR4 represents a potential therapeutic strategy for ccRCC patients with FGFR4 amplification.
Related Concept Videos
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Introduction to Fibroblasts
Targeted Cancer Therapies
There are several types of targeted therapies against...
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation

![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)